Pre-made Nimacimab benchmark antibody ( Whole mAb, anti-CNR1/CB1 therapeutic antibody, Anti-CANN6/CB-R Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Nimacimab biosimilar, Whole mAb, Anti-CNR1/CB1 Antibody: Anti-CANN6/CB-R therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

A first-in-class, only-in-class peripheral antagonist antibody to cannabinoid receptor 1 (CB1) for the treatment of fibrotic, metabolic, and inflammatory diseases including nonalcoholic steatohepatitis (NASH) and diabetic kidney disease (DKD).

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-376-1mg	1mg	3090
GMP-Bios-ab-376-10mg	10mg	Inquiry
GMP-Bios-ab-376-100mg	100mg	Inquiry
GMP-Bios-ab-376-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Nimacimab biosimilar, Whole mAb, Anti-CNR1/CB1 Antibody: Anti-CANN6/CB-R therapeutic antibody
INN Name	Nimacimab
Target	CB1
Format	Whole mAb
Derivation	Humanized
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2018
Year Recommended	2019
Companies	Bird Rock Bio
Conditions Approved	na
Conditions Active	Diabetic nephropathies;Diabetic gastroparesis;Obesity
Conditions Discontinued	Non-alcoholic steatohepatitis;Non-alcoholic fatty liver disease
Development Tech	na